Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boston Scientific recommends Promus stent

Boston Scientific recommends Promus stent

4th July 2008

Boston Scientific has outlined the benefits of its Promus stent system, hailing its low late loss, its ability to reduce re-interventions and its deliverability.

The Promus stent is a private-labelled Xience V everolimus-eluting coronary stent system manufactured by Abbott and distributed by Boston Scientific.

It has been approved by the US Food and Drug Administration and will be launched immediately in the US.

The stent expands the company’s existing portfolio in this area, which currently includes the Taxus Express2 and Taxus Liberte paclitaxel-eluting coronary stent systems, making the company the only firm to offer doctors the choice of two dugs on separate drug-eluting stent (DES) platforms.

Jim Tobin, president and chief executive officer of Boston Scientific, said: “The Promus stent complements our broad DES portfolio and further reinforces Boston Scientific’s leadership in the DES market, as well as our commitment to continued innovation and improved patient outcomes.”

He added the approval of the system by the FDA fulfils the company’s promise of an unparalleled two-drug strategy.

Earlier this week, Abbott said the Xience V stent would become the new standard for DES, having shown superiority to Taxus paclitaxel-eluting coronary stents in head-to-head clinical trials.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.